Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' FLANDRE P' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 20 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Fidouh-Houhou, N; Duval, X; Bissuel, F; Bourbonneux, V; Flandre, P; Ecobichon, JL; Jordn, MC; Vilde, JL; Brun-Vezinet, F; Leport, C
      Salivary cytomegalovirus (CMV) shedding, glycoprotein B genotype distribution, and CMV disease in human immunodeficiency virus-seropositive patients

      CLINICAL INFECTIOUS DISEASES
    2. Descamps, D; Flandre, P; Calvez, V; Peytavin, G; Meiffredy, V; Collin, G; Delaugerre, C; Robert-Delmas, S; Bazin, B; Aboulker, JP; Pialoux, G; Raffi, F; Brun-Vezinet, F
      Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    3. Flandre, P; Saidi, Y
      Estimating the proportion of treatment effect explained by a surrogate marker by D. Y. Lin, T. R. Fleming and V. De Gruttola, Statistics in Medicine,16, 1515-1527 (1997)

      STATISTICS IN MEDICINE
    4. Aboulker, JP; Babiker, AG; Flandre, P; Gazzard, B; Loveday, C; Nunn, AJ; Goudsmit, J; Huraux, JM; van der Noorda, J; Weiss, R; Boucher, C; Schurrman, R; Brun-Vezinet, F; Descamps, D; Jeffries, D; Tedder, R; Weber, J; Darbyshire, JH; Reiss, P; Weverling, G
      An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome

      AIDS
    5. Flandre, P
      Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy

      AIDS
    6. Aboulker, JP; Babiker, AG; Brun-Vezinet, F; Darbyshire, JH; Flandre, P; Gazzard, B; Nunn, AJ; Goodall, R; Aber, V; Bragman, K; Breckenridge, AM; Carbon, C; Charreau, I; Chene, G; Collis, P; Cooper, D; Dormont, J; Fiddian, P; Flepp, M; Goebel, FD; Hooker, M; Lange, J; Luthy, R; Peto, TEA; Reiss, P; Seligmann, M; Stone, AB; Thomis, J; Vella, S; Walckenaer, G; Warrell, D; Weller, IVD; Wilber, R; Yeni, P; Yeo, J; Withnall, R; Goudsmit, J; Huraux, JM; van der Noorda, J; Weiss, R; Boucher, C; Schuurman, R; Descamps, D; Jeffries, D; Tedder, R; Weber, J; Krzyanowski, C; Weverling, G
      HIV-1 RNA response to antiretroviral treatment in 1280 participants in theDelta Trial: an extended virology study

      AIDS
    7. ALBERT JM; IOANNIDIS JPA; REICHELDERFER P; CONWAY B; COOMBS RW; CRANE L; DEMASI R; DIXON DO; FLANDRE P; HUGHES MD; KALISH LA; LARNTZ K; LIN DY; MARSCHNER IC; MUNOZ A; MURRAY J; NEATON J; PETTINELLI C; RIDA W; TAYLOR JMG; WELLES SL
      STATISTICAL ISSUES FOR HIV SURROGATE END-POINTS - POINT COUNTERPOINT/

      Statistics in medicine
    8. FLANDRE P
      ANALYZING SURVIVAL IN THE PRESENCE OF AN AUXILIARY VARIABLE

      Statistics in medicine
    9. PIALOUX G; RAFFI F; BRUNVEZINET F; MEIFFREDY V; FLANDRE P; GASTAUT JA; DELLAMONICA P; YENI P; DELFRAISSY JF; ABOULKER JP
      A RANDOMIZED TRIAL OF 3 MAINTENANCE REGIMENS GIVEN AFTER 3 MONTHS OF INDUCTION THERAPY WITH ZIDOVUDINE, LAMIVUDINE, AND INDINAVIR IN PREVIOUSLY UNTREATED HIV-1-INFECTED PATIENTS

      The New England journal of medicine
    10. GERARD L; LEPORT C; FLANDRE P; HOUHOU B; SALMONCERON D; PEPIN JM; MANDET C; BRUNVEZINET F; VILDE JL
      CYTOMEGALOVIRUS (CMV) VIREMIA AND THE CD4(-IMMUNODEFICIENCY-VIRUS() LYMPHOCYTE COUNT AS PREDICTORS OF CMV DISEASE IN PATIENTS INFECTED WITHHUMAN)

      Clinical infectious diseases
    11. ALCAIS A; ABEL L; DAVID C; TORREZ ME; FLANDRE P; DEDET JP
      RISK-FACTORS FOR ONSET OF CUTANEOUS AND MUCOCUTANEOUS LEISHMANIASIS IN BOLIVIA

      The American journal of tropical medicine and hygiene
    12. ALCAIS A; ABEL L; DAVID C; TORREZ ME; FLANDRE P; DEDET JP
      EVIDENCE FOR A MAJOR GENE CONTROLLING SUSCEPTIBILITY TO TEGUMENTARY LEISHMANIASIS IN A RECENTLY EXPOSED BOLIVIAN POPULATION

      American journal of human genetics
    13. FLANDRE P; BOUFASSA F; GERARD L; CARRE N; PERSOZ A; MEYER L; ROUZIOUX C; BARY M; BURGARD M; DELLAMONICA P; DURANT J; GALLAIS H; MARS ME; GALLAIS J; DORMONT J; DELFRAISSY JF; LEVY A; BOUE F; LEFRERE JJ; LERABLE J; JOUBERT L; CASSUTO JP; REBOULOT B; QUARANTA M; DUPONT B; BEUZELIN C; FOURNIER S; VITTECOQ D; BOLLIOT C; PECHALAT MT; HERSON S; COUTELLIER A; GASTAUT JA; DHIVER C; DROGOUL MP; SERENI D; GOMEZ V; BACHMEYER C; VILDE JL; LEPORT C; COLASSANTE U; KATLAMA C; BRUCKER G; SOBEL A; DUVAL J; MAJERHOLD C; DEFORGES L; KAZATCHKINE M; VELLAY A; BUISSON M; LEBRAS P; GOUJARD C; QUERTAINMONT Y; ANDRIEU JM; EVEN P; GUILLEVIN L; JAROUSSE B; TROGOFF B
      THE USE OF AUXILIARY EVENTS TO IMPROVE THE ANALYSIS OF SURVIVAL FOR HIV-INFECTED PATIENTS - APPLICATION TO THE FRENCH PROSPECTIVE MULTICENTER COHORT (SEROCO)

      Journal of acquired immune deficiency syndromes and human retrovirology
    14. FLANDRE P
      ON THE USE OF AUXILIARY DATA TO ESTIMATE THE SURVIVAL FUNCTION AND ITS VARIANCE - AN APPLICATION TO ACQUIRED-IMMUNODEFICIENCY-SYNDROME

      Journal of clinical epidemiology
    15. GERARD L; FLANDRE P; RAGUIN G; LEGALL JR; VILDE JL; LEPORT C
      LIFE EXPECTANCY IN HOSPITALIZED-PATIENTS WITH AIDS - PROGNOSTIC FACTORS ON ADMISSION

      Journal of palliative care
    16. FLANDRE P; OQUIGLEY J
      A 2-STAGE PROCEDURE FOR SURVIVAL STUDIES WITH SURROGATE END-POINTS

      Biometrics
    17. BERNSTEIN M; MORABIA A; COSTANZA MC; LANDIS JR; ROSS A; FLANDRE P; LUONG BL; KUMANYIKA S; SORENSON A; LOCALIO R
      THE NUTRITIONAL BALANCE OF THE DIET OF TH E ADULT-POPULATION OF GENEVA

      Sozial- und Praventivmedizin
    18. OQUIGLEY J; FLANDRE P
      PREDICTIVE CAPABILITY OF PROPORTIONAL HAZARDS REGRESSION

      Proceedings of the National Academy of Sciences of the United Statesof America
    19. RUIZ J; THILLET J; HUBY T; JAMES RW; ERLICH D; FLANDRE P; FROGUEL P; CHAPMAN J; PASSA P
      ASSOCIATION OF ELEVATED LIPOPROTEIN(A) LEVELS AND CORONARY HEART-DISEASE IN NIDDM PATIENTS - RELATIONSHIP WITH APOLIPOPROTEIN(A) PHENOTYPES

      Diabetologia
    20. FLANDRE P
      REDUCTION IN TRIAL DURATION USING AN AUXI LIARY EVENT

      Revue d'epidemiologie et de sante publique


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/21 alle ore 09:26:04